BioSpace News Archive

Longeveron Inc. (NASDAQ: LGVN) (“Longeveron” or “Company”), a clinical stage biotechnology company developing regenerative medicines for unmet medical needs, today provided a business update and reported its financial results for the fourth quarter and full year of 2022.

Semler Scientific, Inc. announced that it will report financial results for the fourth quarter and full year ended December 31, 2022, after the close of U.S. financial markets on Tuesday, March 21, 2023.

ILiAD Biotechnologies, LLC (ILiAD), a vaccine company utilizing its B-Tech technology to develop novel vaccines against infectious diseases, today announced a peer-reviewed publication in The Lancet.

Lipocine Inc. (NASDAQ: LPCN), a biopharmaceutical company focused on treating Central Nervous System (“CNS”) disorders by leveraging its proprietary platform to develop differentiated products, today announced financial results for the year ended December 31, 2022 and provided a corporate update.

Milestone Scientific Inc. announced that it has commenced sales of CompuFlo® Epidural disposables across three pain management clinics in Colorado: Spine Correction Center of the Rockies; Colorado Clinic; and Colorado Accident and Injury.

Seelos Therapeutics, Inc. announced it has entered into an agreement with a life sciences-focused investment fund for the sale of 12,059,298 shares of its common stock, pre-funded warrants exercisable for an aggregate of 9,340,702 shares of common stock and common warrants exercisable for an aggregate of 26,750,000 shares of common stock.

Kiora Pharmaceuticals, Inc. (NASDAQ: KPRX), (“Kiora” or the “Company”) today announced three abstract acceptances for oral and poster presentation at the 2023 Association for Research in Vision and Ophthalmology (ARVO) meeting in New Orleans, La., April 23-27, 2023.

The Executive Management Board of Medigene AG, an early-stage immuno-oncology platform company focusing on the discovery and development of T cell immunotherapies for solid tumors, adjusted financial guidance for fiscal year 2022.

Further to the announcement made on 8 March 2023 providing notice of a general meeting of the Company to be held on 24 March 2023, and the publication and despatch of a circular to shareholders containing notice of the resolutions to be considered at the GM and form of proxy, the Company announces the following corrections to certain typographical errors identified within the Notice and Form of Proxy:

BioLife Solutions, Inc., a leading supplier of class-defining bioproduction tools and services for the cell and gene therapies and broader biopharma markets, provided commentary on its current banking relationship with Silicon Valley Bank.